Loading...

Valentin Feichtenschlager, MD

Title(s)Postdoctoral Scholar, Dermatology
SchoolSchool of Medicine
Phone415-425-0890
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Feichtenschlager V, Weihsengruber F, Richter L, Vujic I, Rappersberger K, Posch C. Clinical melanoma characteristics and survival-a single-center retrospective study between 2000 and 2010. Wien Med Wochenschr. 2019 Oct; 169(13-14):323-330. PMID: 30649651.
      View in: PubMed
    2. L. Chen, V. Feichtenschlager, M. Vujic, A. Lee, H. Kao, J. Zheng, S. Ortiz. 185 The antisense lncRNA transcript RP11-7O11.3: Shedding light upon a novel and crucial player in NRAS mutant melanoma. Journal of Investigative Dermatology. 2018 May 1; 138(5):s31.
      View in: Publisher Site
    3. V. Feichtenschlager, L. Chen, M. Vujic, A. Lee, H. Kao, J. Zheng, S. Ortiz. 184 Discovering the hidden elements of cancer: Targeting the lncrna ac004540.4 reveals its critical role in nras mutant melanoma. Journal of Investigative Dermatology. 2018 May 1; 138(5):s31.
      View in: Publisher Site
    4. C. Posch, V. Feichtenschlager, F. Weihsengruber, K. Rappersberger. 497 Eleven years of melanoma patient management – observations and trends from a single-center study in Austria. Journal of Investigative Dermatology. 2016 Sep 1; 136(9):s245.
      View in: Publisher Site
    5. Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget. 2014 Sep 15; 5(17):7936-44. PMID: 25277205.
      View in: PubMed
    6. Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K. Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer. 2014 Mar 18; 110(6):1427-32. PMID: 24518593.
      View in: PubMed
    7. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 05; 110(10):4015-20. PMID: 23431193.
      View in: PubMed